- Citations, last 5 years
- 1
- Works, last 5 years
- 7
- h-index
- 2
- Scientists listed
- 1
- Grants since 2016
- 8
Grants received
2025–2027 · research · R44
Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy
Theresa A Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients
Theresa Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients
Theresa Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health
2022–2023 · research · R43
AVM0703 combined with Non-Hodgkin's Lymphoma standard of care to enhance complete response rates without additional toxicities
Theresa Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health
2020–2022 · research · R43
A novel non-toxic preconditioning regimen for cancer cell therapy
Theresa Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Targeted lympho-ablation as an alternative to HSCT to cure T1D
Theresa Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health
2019–2025 · research · R44
Targeted Lymphoablation as an alternative to HSCT to cure T1D
Theresa Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health
2019–2024 · research · R44
Targeted Lymphoablation as an alternative to HSCT to cure T1D
Theresa Deisher · AVM Biotechnology (United States) · funded by National Institutes of Health